In a double-blind comparative trial, 100 men with uncomplicated gonorrhea caused by beta-
lactamase-negative Neisseria gonorrhoeae were treated with a single 0.25-g dose of …

Ciprofloxacin is a new, oral, broad spectrum fluoroquinolone antibiotic which has a long
serum half-life, a low incidence of significant adverse reactions, and is administered twice …

A new method of assessing the bactericidal activity of quinolones and other antibacterial
agents, known as the bactericidal index or BI, is introduced and discussed. The BI …

Some of the new quinolone derivatives may be of value in the treatment of respiratory tract
infections. It has been demonstrated that enoxacin, pefloxacin and ciprofloxacin, but not …

Ciprofloxacin is widely reported to lower theophylline clearance in patients. Since
cyclosporin and theophylline are metabolized by cytochrome P‐450 enzymes in the human …

Objectives: Drug administration to debilitated elderly patients on enteral feeding through a
nasogastric tube (NGT) can modify the pharmacokinetic characteristics of the drug and …

Ciprofloxacin at a concentration of 2 µg/mL inhibited the growth of∼ 90% of 584 strains of
aerobic bacteria isolated from cultures of blood drawn from septicemic patients. An increase …

A retrospective analysis of the relationship between estimated pharmacokinetic/
pharmacodynamic indices and the reported efficacy of ciprofloxacin has been carried out …

Background and objective: Pharmacokinetic drug interactions may result in a decrease or
increase in the oral bioavailability of some drugs. Therefore, coadministration of drugs …

Oral ciprofloxacin was used at doses ranging from 500 mg to 1500 mg twice daily for 15 to
476 (mean 139) days for treatment of acute or chronic osteomyelitis in 38 patients, and acute …